Works matching DE "BARICITINIB"
Results: 332
Comparative Efficacy and Safety of JAK Inhibitors in the Management of Rheumatoid Arthritis: A Network Meta-Analysis.
- Published in:
- Pharmaceuticals (14248247), 2025, v. 18, n. 2, p. 178, doi. 10.3390/ph18020178
- By:
- Publication type:
- Article
Switching JAK inhibitors: evaluating baricitinib's effectiveness in alopecia areata after tofacitinib failure.
- Published in:
- Archives of Dermatological Research, 2025, v. 317, n. 1, p. 1, doi. 10.1007/s00403-025-04035-y
- By:
- Publication type:
- Article
Baricitinib combined with methylprednisolone on inflammatory factors in patients with severe pneumonia.
- Published in:
- Advances in Continuous & Discrete Models, 2025, v. 2025, n. 1, p. 1, doi. 10.1186/s13662-025-03904-0
- By:
- Publication type:
- Article
A prospective randomized-controlled non-blinded comparative study of the JAK inhibitor (baricitinib) with TNF-α inhibitors and conventional DMARDs in a sample of Egyptian rheumatoid arthritis patients.
- Published in:
- Clinical Rheumatology, 2024, v. 43, n. 12, p. 3657, doi. 10.1007/s10067-024-07194-x
- By:
- Publication type:
- Article
Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs.
- Published in:
- Clinical Rheumatology, 2024, v. 43, n. 6, p. 2133, doi. 10.1007/s10067-024-06980-x
- By:
- Publication type:
- Article
Rheumatoid arthritis with pulmonary accelerated rheumatoid nodules treated by baricitinib: a case-based review.
- Published in:
- Clinical Rheumatology, 2024, v. 43, n. 2, p. 775, doi. 10.1007/s10067-023-06773-8
- By:
- Publication type:
- Article
Does baricitinib reduce disease activity in patients with systemic lupus erythematosus? A systematic review and meta-analysis of randomized controlled trials.
- Published in:
- Clinical Rheumatology, 2024, v. 43, n. 2, p. 579, doi. 10.1007/s10067-023-06731-4
- By:
- Publication type:
- Article
Are all JAK inhibitors for the treatment of rheumatoid arthritis equivalent? An adjusted indirect comparison of the efficacy of tofacitinib, baricitinib, upadacitinib, and filgotinib.
- Published in:
- Clinical Rheumatology, 2023, v. 42, n. 12, p. 3225, doi. 10.1007/s10067-023-06787-2
- By:
- Publication type:
- Article
A case of hemophagocytic lymphohistiocytosis with a significant response to baricitinib: a first report with review of literature.
- Published in:
- 2023
- By:
- Publication type:
- Case Study
Safety of JAK inhibitor use in patients with rheumatoid arthritis who developed herpes zoster after receiving JAK inhibitors.
- Published in:
- Clinical Rheumatology, 2022, v. 41, n. 6, p. 1659, doi. 10.1007/s10067-022-06096-0
- By:
- Publication type:
- Article
Comparison of the effects of baricitinib and tocilizumab on disease activity in patients with rheumatoid arthritis: a propensity score matching analysis.
- Published in:
- Clinical Rheumatology, 2021, v. 40, n. 8, p. 3143, doi. 10.1007/s10067-021-05815-3
- By:
- Publication type:
- Article
Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort study.
- Published in:
- Clinical Rheumatology, 2021, v. 40, n. 7, p. 2673, doi. 10.1007/s10067-021-05609-7
- By:
- Publication type:
- Article
Baricitinib as treatment for isolated severe nail lichen planus.
- Published in:
- 2023
- By:
- Publication type:
- Letter to the Editor
RECOVERY Trial Data on Baricitinib in Patients Hospitalized with Coronavirus Disease 2019.
- Published in:
- touchREVIEWS in Infectious Diseases, 2022, v. 1, n. 1, p. 10, doi. 10.17925/ID.2022.1.1.10
- By:
- Publication type:
- Article
Alopezie - ein altes Problem mit neuen Behandlungsoptionen.
- Published in:
- Kosmetische Medizin + Ästhetische Chirurgie, 2024, v. 45, n. 3, p. 137
- By:
- Publication type:
- Article
Publisher Correction: Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Consensus Recommendations for the Management of Atopic Dermatitis in the United Arab Emirates.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 9, p. 2299, doi. 10.1007/s13555-024-01247-4
- By:
- Publication type:
- Article
Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 7, p. 1959, doi. 10.1007/s13555-024-01208-x
- By:
- Publication type:
- Article
Baricitinib Improvement Across Regions in Atopic Dermatitis Patients with Baseline Body Surface Area up to 40% and Severe Itch.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 6, p. 1561, doi. 10.1007/s13555-024-01171-7
- By:
- Publication type:
- Article
Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 4, p. 919, doi. 10.1007/s13555-024-01135-x
- By:
- Publication type:
- Article
Clinical Benefits of Baricitinib Therapy According to Scalp Hair Regrowth in Patients with Severe Alopecia Areata.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 12, p. 3209, doi. 10.1007/s13555-023-01063-2
- By:
- Publication type:
- Article
Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 12, p. 2951, doi. 10.1007/s13555-023-01044-5
- By:
- Publication type:
- Article
Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 12, p. 3181, doi. 10.1007/s13555-023-01033-8
- By:
- Publication type:
- Article
Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 11, p. 2869, doi. 10.1007/s13555-023-01030-x
- By:
- Publication type:
- Article
Pooled Safety Analysis of Baricitinib in Adult Participants with Atopic Dermatitis in the Japanese Subpopulation from Six Randomized Clinical Trials.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 12, p. 2765, doi. 10.1007/s13555-022-00828-5
- By:
- Publication type:
- Article
Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 6, p. 1481, doi. 10.1007/s13555-022-00734-w
- By:
- Publication type:
- Article
Clinical Tailoring of Baricitinib 2 mg in Atopic Dermatitis: Baseline Body Surface Area and Rapid Onset of Action Identifies Response at Week 16.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 1, p. 137, doi. 10.1007/s13555-021-00640-7
- By:
- Publication type:
- Article
Baricitinib Rapidly Improves Skin Pain Resulting in Improved Quality of Life for Patients with Atopic Dermatitis: Analyses from BREEZE-AD1, 2, and 7.
- Published in:
- Dermatology & Therapy, 2021, v. 11, n. 5, p. 1599, doi. 10.1007/s13555-021-00577-x
- By:
- Publication type:
- Article
Itch and Sleep Improvements with Baricitinib in Patients with Atopic Dermatitis: A Post Hoc Analysis of 3 Phase 3 Studies.
- Published in:
- Dermatology & Therapy, 2021, v. 11, n. 3, p. 971, doi. 10.1007/s13555-021-00534-8
- By:
- Publication type:
- Article
A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA.
- Published in:
- 2020
- By:
- Publication type:
- journal article
A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-2.
- Published in:
- Annals of Internal Medicine, 2024, v. 177, n. 3, p. 343, doi. 10.7326/M23-2593
- By:
- Publication type:
- Article
Inhibition of JAK-STAT Signaling by Baricitinib Reduces Interferon-γ-Induced CXCL10 Production in Human Salivary Gland Ductal Cells.
- Published in:
- Inflammation, 2021, v. 44, n. 1, p. 206, doi. 10.1007/s10753-020-01322-w
- By:
- Publication type:
- Article
A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Baricitinib reduces 30‐day mortality in older adults with moderate‐to‐severe COVID‐19 pneumonia.
- Published in:
- Journal of the American Geriatrics Society, 2021, v. 69, n. 10, p. 2752, doi. 10.1111/jgs.17357
- By:
- Publication type:
- Article
Therapeutic Maintenance of Janus Kinase Inhibitors in Real Life for Rheumatoid Arthritis: Retrospective Study.
- Published in:
- Journal of Clinical Medicine, 2024, v. 13, n. 16, p. 4608, doi. 10.3390/jcm13164608
- By:
- Publication type:
- Article
The Real-World Effectiveness, Persistence, Adherence, and Safety of Janus Kinase Inhibitor Baricitinib in Rheumatoid Arthritis: A Long-Term Study.
- Published in:
- Journal of Clinical Medicine, 2024, v. 13, n. 9, p. 2517, doi. 10.3390/jcm13092517
- By:
- Publication type:
- Article
Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib.
- Published in:
- Journal of Clinical Medicine, 2023, v. 12, n. 20, p. 6690, doi. 10.3390/jcm12206690
- By:
- Publication type:
- Article
A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience.
- Published in:
- Journal of Clinical Medicine, 2023, v. 12, n. 13, p. 4527, doi. 10.3390/jcm12134527
- By:
- Publication type:
- Article
Characteristics of Patients Treated with JAK Inhibitors in Rheumatoid Arthritis before versus after VTE Risk Warnings.
- Published in:
- Journal of Clinical Medicine, 2023, v. 12, n. 1, p. 207, doi. 10.3390/jcm12010207
- By:
- Publication type:
- Article
Efficacy and Safety of JAK Inhibitors for Rheumatoid Arthritis: A Meta-Analysis.
- Published in:
- Journal of Clinical Medicine, 2022, v. 11, n. 15, p. 4459, doi. 10.3390/jcm11154459
- By:
- Publication type:
- Article
Anakinra versus Baricitinib: Different Strategies for Patients Hospitalized with COVID-19 †.
- Published in:
- Journal of Clinical Medicine, 2021, v. 10, n. 17, p. 4019, doi. 10.3390/jcm10174019
- By:
- Publication type:
- Article
Therapeutic Maintenance of Baricitinib and Tofacitinib in Real Life.
- Published in:
- Journal of Clinical Medicine, 2020, v. 9, n. 10, p. 3319, doi. 10.3390/jcm9103319
- By:
- Publication type:
- Article
The JAK1/2 Inhibitor Baricitinib Mitigates the Spike-Induced Inflammatory Response of Immune and Endothelial Cells In Vitro.
- Published in:
- Biomedicines, 2022, v. 10, n. 9, p. 2324, doi. 10.3390/biomedicines10092324
- By:
- Publication type:
- Article
Upconverting-photon quenching-mediated perforation influx as an intracellular delivery method using posAuNP@UCNPs nanocomposites for osteoarthritis treatment.
- Published in:
- Nano Convergence, 2024, v. 11, n. 1, p. 1, doi. 10.1186/s40580-023-00409-y
- By:
- Publication type:
- Article
P5‐47: Safety and efficacy of remdesivir, baricitinib and high‐dose steroid combination therapy in patients hospitalized with COVID‐19.
- Published in:
- Respirology, 2021, v. 26, p. 175, doi. 10.1111/resp.14150_254
- Publication type:
- Article
P5‐47: Safety and efficacy of remdesivir, baricitinib and high‐dose steroid combination therapy in patients hospitalized with COVID‐19.
- Published in:
- Respirology, 2021, v. 26, p. 175, doi. 10.1111/resp.14150_254
- Publication type:
- Article
Treatment of moderate-to-severe alopecia areata in patients over the age of 65 years with baricitinib.
- Published in:
- Clinical & Experimental Dermatology, 2024, v. 49, n. 8, p. 875, doi. 10.1093/ced/llae033
- By:
- Publication type:
- Article
Neutrophilic dermatosis of the dorsal hands treated with baricitinib.
- Published in:
- Clinical & Experimental Dermatology, 2023, v. 48, n. 11, p. 1274, doi. 10.1093/ced/llad245
- By:
- Publication type:
- Article
Major improvement of very severe alopecia areata in patients treated with the combination of baricitinib and low doses of corticosteroids: an eight-case series.
- Published in:
- Clinical & Experimental Dermatology, 2023, v. 48, n. 11, p. 1258, doi. 10.1093/ced/llad239
- By:
- Publication type:
- Article
Early improvements in signs and symptoms predict clinical response to baricitinib in patients with moderate-to-severe atopic dermatitis.
- Published in:
- Clinical & Experimental Dermatology, 2023, v. 48, n. 8, p. 881, doi. 10.1093/ced/llad129
- By:
- Publication type:
- Article